Neurourology and urodynamics | 2021
Adjustable continence therapy (ACT®) balloons to treat neurogenic and non-neurogenic female urinary incontinence.
Abstract
AIMS\nTo compare efficacy and safety between neurogenic and non-neurogenic women after adjustable continence therapy (ACT®) balloons implantation to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency.\n\n\nMETHODS\nIn the present retrospective multicentric study, all neurogenic and non-neurogenic women implanted with ACT® balloons between 2000 and 2018 were considered for inclusion. Efficacy was compared 1 year after implantation, and women were allocated in three different groups as follows. Success: maximum 1 pad per day and patient s impression of improvement assessed using a numeral rating scale (NRS)\u2009≥8/10. Improvement: decrease of daily pad use and/or NRS\u2009≥5/10. Failure: increase or stability of daily pad use or NRS\u2009<5/10. Overall surgical complications and explantations were compared 1 year after implantation.\n\n\nRESULTS\nAmong the 277 included women, 51 presented with a neurologic underlying disease. Mean age at implantation was 68.5 years. There was no significant difference in efficacy between neurogenic and non-neurogenic women with a success rate of 39.2% and 36.3%, respectively (p\u2009=\u20090.69). Similarly, improvement rate was reported to be 31.4% and 33.6%, in neurogenic and non-neurogenic women, respectively (p\u2009=\u20090.92). The overall surgical complications rate (24% vs. 34.5%, p\u2009=\u20090.15) and the explantation rate (19.6% vs. 28.8%, p\u2009=\u20090.18) were not significantly different.\n\n\nCONCLUSION\nACT balloons may be proposed to treat mixed or SUI in females with ISD. Efficacy and safety profiles appear to be similar in both neurogenic and non-neurogenic patients.